Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
ETIC-LM: Tucatinib, Capecitabine, and Intrathecal Trastuzumab for HER2+ Breast Cancer with Leptomeningeal Metastases
NCT05800275Phase 2Recruiting
- Sponsor
- Unicancer
- Start
- Dec 2023
- Primary completion
- Dec 2026
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of tucatinib in breast cancer, sponsored by Unicancer. Primary endpoint: Overall Survival Rate at 12 Months. Started Dec 2023; status: recruiting.
02
Drugs
tucatinib
03
Conditions
breast cancer
Beyond the preview
Go deeper on NCT05800275.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT05800275.